352 related articles for article (PubMed ID: 29046433)
1. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.
Shen C; Chen J; Li R; Zhang M; Wang G; Stegalkina S; Zhang L; Chen J; Cao J; Bi X; Anderson SF; Alefantis T; Zhang M; Cai X; Yang K; Zheng Q; Fang M; Yu H; Luo W; Zheng Z; Yuan Q; Zhang J; Wai-Kuo Shih J; Kleanthous H; Chen H; Chen Y; Xia N
Sci Transl Med; 2017 Oct; 9(412):. PubMed ID: 29046433
[TBL] [Abstract][Full Text] [Related]
2. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency.
Shen C; Zhang M; Chen Y; Zhang L; Wang G; Chen J; Chen S; Li Z; Wei F; Chen J; Yang K; Guo S; Wang Y; Zheng Q; Yu H; Luo W; Zhang J; Chen H; Chen Y; Xia N
Theranostics; 2019; 9(1):210-231. PubMed ID: 30662563
[TBL] [Abstract][Full Text] [Related]
3. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
[TBL] [Abstract][Full Text] [Related]
4. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
[TBL] [Abstract][Full Text] [Related]
5. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.
Ermler ME; Kirkpatrick E; Sun W; Hai R; Amanat F; Chromikova V; Palese P; Krammer F
J Virol; 2017 Jun; 91(12):. PubMed ID: 28356526
[TBL] [Abstract][Full Text] [Related]
7. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
[TBL] [Abstract][Full Text] [Related]
8. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies.
Vigil A; Frias-Staheli N; Carabeo T; Wittekind M
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847855
[TBL] [Abstract][Full Text] [Related]
9. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin.
Laursen NS; Friesen RHE; Zhu X; Jongeneelen M; Blokland S; Vermond J; van Eijgen A; Tang C; van Diepen H; Obmolova G; van der Neut Kolfschoten M; Zuijdgeest D; Straetemans R; Hoffman RMB; Nieusma T; Pallesen J; Turner HL; Bernard SM; Ward AB; Luo J; Poon LLM; Tretiakova AP; Wilson JM; Limberis MP; Vogels R; Brandenburg B; Kolkman JA; Wilson IA
Science; 2018 Nov; 362(6414):598-602. PubMed ID: 30385580
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.
Tan GS; Lee PS; Hoffman RM; Mazel-Sanchez B; Krammer F; Leon PE; Ward AB; Wilson IA; Palese P
J Virol; 2014 Dec; 88(23):13580-92. PubMed ID: 25210195
[TBL] [Abstract][Full Text] [Related]
11. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses.
Oh HL; Akerström S; Shen S; Bereczky S; Karlberg H; Klingström J; Lal SK; Mirazimi A; Tan YJ
J Virol; 2010 Aug; 84(16):8275-86. PubMed ID: 20519402
[TBL] [Abstract][Full Text] [Related]
12. Human monoclonal antibodies broadly neutralizing against influenza B virus.
Yasugi M; Kubota-Koketsu R; Yamashita A; Kawashita N; Du A; Sasaki T; Nishimura M; Misaki R; Kuhara M; Boonsathorn N; Fujiyama K; Okuno Y; Nakaya T; Ikuta K
PLoS Pathog; 2013 Feb; 9(2):e1003150. PubMed ID: 23408886
[TBL] [Abstract][Full Text] [Related]
13. Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.
Wohlbold TJ; Podolsky KA; Chromikova V; Kirkpatrick E; Falconieri V; Meade P; Amanat F; Tan J; tenOever BR; Tan GS; Subramaniam S; Palese P; Krammer F
Nat Microbiol; 2017 Oct; 2(10):1415-1424. PubMed ID: 28827718
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.
Kirkpatrick E; Henry C; McMahon M; Jiang K; Strohmeier S; van Bakel H; Wilson PC; Krammer F
J Virol; 2020 Nov; 94(23):. PubMed ID: 32907980
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
[TBL] [Abstract][Full Text] [Related]
16. An epitope on the stem region of hemagglutinin of H1N1 influenza A virus recognized by neutralizing monoclonal antibody.
Yan L; Wang H; Sun L; Liu Y; Sun J; Zhao X; Li Y; Xie X; Hu J
Biochem Biophys Res Commun; 2019 Oct; 518(2):319-324. PubMed ID: 31421820
[TBL] [Abstract][Full Text] [Related]
17. Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.
Moser MJ; Hatta Y; Gabaglia C; Sanchez A; Dias P; Sarawar S; Kawaoka Y; Hatta M; Neumann G; Bilsel P
Vaccine; 2019 Jul; 37(32):4533-4542. PubMed ID: 31280945
[TBL] [Abstract][Full Text] [Related]
18. Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.
Kirchenbaum GA; Carter DM; Ross TM
J Virol; 2016 Jan; 90(2):1116-28. PubMed ID: 26559834
[TBL] [Abstract][Full Text] [Related]
19. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.
Zanin M; Keck ZY; Rainey GJ; Lam CY; Boon AC; Rubrum A; Darnell D; Wong SS; Griffin Y; Xia J; Webster RG; Webby R; Johnson S; Foung S
J Virol; 2015 Apr; 89(8):4549-61. PubMed ID: 25673719
[TBL] [Abstract][Full Text] [Related]
20. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
